5月6日，神经分泌生物科学（NBIX）在夜盘交易中大涨7.87%，引发投资者关注。尽管公司最新公布的季度业绩低于预期，但分析师对其前景仍持乐观态度。
根据公司发布的财报，截至3月31日的季度调整后每股收益为8美分，远低于分析师平均预期的54美分，也低于去年同期的42美分。然而，公司的营收表现较为亮眼，同比增长11.1%，达到5.726亿美元，超过分析师预期的5.5933亿美元。
尽管季度业绩不及预期，但华尔街分析师仍对神经分泌生物科学保持信心。加拿大皇家银行（RBC）将该公司的目标价从137美元上调至145美元。目前，分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为160美元，显示出对公司长期发展前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.